Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year

Reports Q3 revenue $420,000 vs $3.067M last year. "We continue to advance our proprietary mesenchymal stem cell secretome platform and expect to submit an investigational new drug application with the U.S. Food and Drug Administration during the fourth quarter of 2022 for KPI-012 for the treatment of PCED," said Mark Iwicki, Chief Executive Officer and Chairman of Kala. "Pending IND clearance, we plan to initiate our Phase 2/3 clinical trial in the fourth quarter of 2022, marking a significant step toward our goal of delivering the promise of MSC-S-based therapies to people living with rare and severe ocular diseases."